Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CHRS

CHRS - Coherus Biosciences Inc Stock Price, Fair Value and News

$1.63-0.06 (-3.55%)
Market Closed

38/100

CHRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

38/100

CHRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CHRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CHRS Price Action

Last 7 days

-10.4%

Last 30 days

-20.1%

Last 90 days

20.7%

Trailing 12 Months

83.2%

CHRS RSI Chart

CHRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CHRS Valuation

Market Cap

244.3M

Price/Earnings (Trailing)

1.45

Price/Sales (Trailing)

5.79

EV/EBITDA

-0.9

Price/Free Cashflow

-1.76

CHRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CHRS Fundamentals

CHRS Revenue

Revenue (TTM)

42.2M

Rev. Growth (Yr)

64.85%

Rev. Growth (Qtr)

10.17%

CHRS Earnings

Earnings (TTM)

168.0M

Earnings Growth (Yr)

25.75%

Earnings Growth (Qtr)

-5.94%

CHRS Profitability

EBT Margin

-434.23%

Return on Equity

275.39%

Return on Assets

65.04%

Free Cashflow Yield

-56.69%

CHRS Investor Care

Shares Dilution (1Y)

29.33%

Diluted EPS (TTM)

1.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202531.7M31.6M37.2M42.2M
2024137.2M100.3M63.3M26.4M
2023183.4M181.9M211.1M174.1M
2022303.6M276.1M239.1M211.0M
2021442.7M394.6M363.6M326.6M
2020435.1M487.4M489.3M475.8M
2019284.9M308.6M332.3M356.1M
20170213.8M237.5M261.2M
201636.6M43.8M199.5M190.1M
201533.3M35.2M26.3M30.0M
20145.8M10.3M25.8M31.1M
20132.1M2.3M2.5M2.8M
20120001.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Coherus Biosciences Inc

CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
 CEO
 WEBSITEcoherus.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES294

Coherus Biosciences Inc Frequently Asked Questions

CHRS is the stock ticker symbol of Coherus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Coherus Biosciences Inc is 244.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CHRS's PE ratio (Price to Earnings) is 1.45 and Price to Sales (PS) ratio is 5.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CHRS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Coherus Biosciences Inc has provided -0.215 (multiply by 100 for percentage) rate of return.